Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis: A Randomized Controlled Trial

The treatment of cutaneous leishmaniasis (CL) caused by Leishmania braziliensis in Brazil with pentavalent antimony (Sb ) is associated with a high rate of failure, up to 45% of cases. In addition, Sb can only administered parenterally and has important toxic effect. An effective, safe, and oral tre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases Jg. 64; H. 1; S. 67
Hauptverfasser:	Prates, Fernanda V de O, Dourado, Mayra E F, Silva, Silvana C, Schriefer, Albert, Guimarães, Luiz H, Brito, Maria das Graças O, Almeida, Juliana, Carvalho, Edgar M, Machado, Paulo R L
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.01.2017
Schlagworte:	Adolescent Adult Antimony - administration & dosage Antimony - adverse effects Antimony - therapeutic use Antiprotozoal Agents - administration & dosage Antiprotozoal Agents - adverse effects Antiprotozoal Agents - therapeutic use Brazil Female Fluconazole - administration & dosage Fluconazole - adverse effects Fluconazole - therapeutic use Humans Leishmania braziliensis - drug effects Leishmania braziliensis - genetics Leishmaniasis, Cutaneous - diagnosis Leishmaniasis, Cutaneous - drug therapy Leishmaniasis, Cutaneous - parasitology Male Middle Aged Treatment Outcome Young Adult fluconazole cutaneous leishmaniasis pentavalent antimony Leishmania (V.) braziliensis
ISSN:	1537-6591, 1537-6591
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!